Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib-Lenalidomide-Dexamethasone vs Lenalidomide in Residual Multiple Myeloma
NCT02389517Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Mar 2015
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ixazomib in multiple myeloma (MM) (2 arms), sponsored by University of Chicago. Primary endpoint: Percentage of Participants With Minimal Residual Disease Negativity at 12 months. Started Mar 2015; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02389517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02389517.